Construction of recombinant attenuated Salmonella enterica serovar typhimurium vaccine vector strains for safety in newborn and infant mice

Bronwyn M. Gunn, Soo Young Wanda, Dana Burshell, Caihong Wang, Roy Curtiss

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Recombinant bacterial vaccines must be safe, efficacious, and well tolerated, especially when administered to newborns and infants to prevent diseases of early childhood. Many means of attenuation have been shown to render vaccine strains susceptible to host defenses or unable to colonize lymphoid tissue effectively, thus decreasing their immunogenicity. We have constructed recombinant attenuated Salmonella vaccine strains that display high levels of attenuation while retaining the ability to induce high levels of immunogenicity and are well tolerated in high doses when administered to infant mice as young as 24 h old. The strains contain three means of regulated delayed attenuation, as well as a constellation of additional mutations that aid in enhancing safety, regulate antigen expression, and reduce disease symptoms commonly associated with Salmonella infection. The vaccine strains are well tolerated when orally administered to infant mice 24 h old at doses as high as 3.5 × 10 8 CFU.

Original languageEnglish (US)
Pages (from-to)354-362
Number of pages9
JournalClinical and Vaccine Immunology
Volume17
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Synthetic Vaccines
Salmonella
Salmonella enterica
Vaccines
Salmonella Vaccines
Newborn Infant
Bacterial Vaccines
Safety
Attenuated Vaccines
Salmonella Infections
Lymphoid Tissue
Tissue
Antigens
Mutation
Serogroup

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

Construction of recombinant attenuated Salmonella enterica serovar typhimurium vaccine vector strains for safety in newborn and infant mice. / Gunn, Bronwyn M.; Wanda, Soo Young; Burshell, Dana; Wang, Caihong; Curtiss, Roy.

In: Clinical and Vaccine Immunology, Vol. 17, No. 3, 03.2010, p. 354-362.

Research output: Contribution to journalArticle

Gunn, Bronwyn M. ; Wanda, Soo Young ; Burshell, Dana ; Wang, Caihong ; Curtiss, Roy. / Construction of recombinant attenuated Salmonella enterica serovar typhimurium vaccine vector strains for safety in newborn and infant mice. In: Clinical and Vaccine Immunology. 2010 ; Vol. 17, No. 3. pp. 354-362.
@article{03846511fc034476b4db9b6aee1eb216,
title = "Construction of recombinant attenuated Salmonella enterica serovar typhimurium vaccine vector strains for safety in newborn and infant mice",
abstract = "Recombinant bacterial vaccines must be safe, efficacious, and well tolerated, especially when administered to newborns and infants to prevent diseases of early childhood. Many means of attenuation have been shown to render vaccine strains susceptible to host defenses or unable to colonize lymphoid tissue effectively, thus decreasing their immunogenicity. We have constructed recombinant attenuated Salmonella vaccine strains that display high levels of attenuation while retaining the ability to induce high levels of immunogenicity and are well tolerated in high doses when administered to infant mice as young as 24 h old. The strains contain three means of regulated delayed attenuation, as well as a constellation of additional mutations that aid in enhancing safety, regulate antigen expression, and reduce disease symptoms commonly associated with Salmonella infection. The vaccine strains are well tolerated when orally administered to infant mice 24 h old at doses as high as 3.5 × 10 8 CFU.",
author = "Gunn, {Bronwyn M.} and Wanda, {Soo Young} and Dana Burshell and Caihong Wang and Roy Curtiss",
year = "2010",
month = "3",
doi = "10.1128/CVI.00412-09",
language = "English (US)",
volume = "17",
pages = "354--362",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Construction of recombinant attenuated Salmonella enterica serovar typhimurium vaccine vector strains for safety in newborn and infant mice

AU - Gunn, Bronwyn M.

AU - Wanda, Soo Young

AU - Burshell, Dana

AU - Wang, Caihong

AU - Curtiss, Roy

PY - 2010/3

Y1 - 2010/3

N2 - Recombinant bacterial vaccines must be safe, efficacious, and well tolerated, especially when administered to newborns and infants to prevent diseases of early childhood. Many means of attenuation have been shown to render vaccine strains susceptible to host defenses or unable to colonize lymphoid tissue effectively, thus decreasing their immunogenicity. We have constructed recombinant attenuated Salmonella vaccine strains that display high levels of attenuation while retaining the ability to induce high levels of immunogenicity and are well tolerated in high doses when administered to infant mice as young as 24 h old. The strains contain three means of regulated delayed attenuation, as well as a constellation of additional mutations that aid in enhancing safety, regulate antigen expression, and reduce disease symptoms commonly associated with Salmonella infection. The vaccine strains are well tolerated when orally administered to infant mice 24 h old at doses as high as 3.5 × 10 8 CFU.

AB - Recombinant bacterial vaccines must be safe, efficacious, and well tolerated, especially when administered to newborns and infants to prevent diseases of early childhood. Many means of attenuation have been shown to render vaccine strains susceptible to host defenses or unable to colonize lymphoid tissue effectively, thus decreasing their immunogenicity. We have constructed recombinant attenuated Salmonella vaccine strains that display high levels of attenuation while retaining the ability to induce high levels of immunogenicity and are well tolerated in high doses when administered to infant mice as young as 24 h old. The strains contain three means of regulated delayed attenuation, as well as a constellation of additional mutations that aid in enhancing safety, regulate antigen expression, and reduce disease symptoms commonly associated with Salmonella infection. The vaccine strains are well tolerated when orally administered to infant mice 24 h old at doses as high as 3.5 × 10 8 CFU.

UR - http://www.scopus.com/inward/record.url?scp=77649262349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649262349&partnerID=8YFLogxK

U2 - 10.1128/CVI.00412-09

DO - 10.1128/CVI.00412-09

M3 - Article

C2 - 20053874

AN - SCOPUS:77649262349

VL - 17

SP - 354

EP - 362

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 3

ER -